z-logo
open-access-imgOpen Access
Low expression of Cyfip1 may be a potential biomarker in nasopharyngeal carcinoma
Author(s) -
Xiangsong Shi,
X. Chen,
W. C. Li,
Lei Mo,
Zenan Lin,
Y. Y. Li,
Zheng Yang,
W. N. Mo
Publication year - 2018
Publication title -
neoplasma
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.628
H-Index - 50
eISSN - 1338-4317
pISSN - 0028-2685
DOI - 10.4149/neo_2018_170318n194
Subject(s) - nasopharyngeal carcinoma , messenger rna , cancer research , biomarker , real time polymerase chain reaction , medicine , oncology , lymph node metastasis , pathology , metastasis , biology , gene , cancer , radiation therapy , biochemistry
Cytoplasmic FMR1 interacting protein 1 (Cyfip1) is a new candidate tumor suppressor gene, which may play an impor- tant role in the occurrence and development of cancers. However, the role of Cyfip1 in nasopharyngeal carcinoma (NPC) remains poorly known. The aim of this study was to investigate the Cyfip1 mRNA expression in NPC and its association with clinicopathological features. The study population comprised 114 Chinese individuals, including 69 NPC tissues and 45 non-cancerous nasopharyngeal tissues. We used real-time fluorescent relatively quantitative PCR to evaluate the Cyfip1 mRNA expression in NPC tissues and non-cancerous nasopharyngeal tissues. The expression level of Cyfip1 mRNA was significantly lower in patients with NPC than in the control samples (p=0.001). Furthermore, low expression level of Cyfip1 mRNA was significantly associated with invasive range (T3-T4 vs T1-T2, p=0.001), lymph node metastasis (N1-N3 vs   N0, p=0.010), distant metastases (M1 vs M0, p=0.040) and clinical stage (III-IV vs I-II, p<0.001). Our results suggest the association between Cyfip1 mRNA expression and NPC. Detecting the expression of Cyfip1 may provide clinically useful information for diagnosis, progression and treatment methods in NPC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here